Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
129.44
-1.70 (-1.30%)
May 23, 2024, 4:00 PM EDT - Market closed

Company Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.

It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S
Ascendis Pharma logo
Country Denmark
Founded 2006
IPO Date Jan 28, 2015
Industry Biotechnology
Sector Healthcare
Employees 879
CEO Jan Moller Mikkelsen

Contact Details

Address:
Tuborg Boulevard 12
Hellerup, G7 DK-2900
Denmark
Phone 45 70 22 22 44
Website ascendispharma.com

Stock Details

Ticker Symbol ASND
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001612042
CUSIP Number 04351P101
ISIN Number US04351P1012
SIC Code 2834

Key Executives

Name Position
Jan Moller Mikkelsen President, Chief Executive Officer, Member of Executive Board and Executive Director
Scott T. Smith Chief Financial Officer, Executive Vice President and Member of Executive Board
Lotte Sonderbjerg Executive Vice President, Chief Administrative Officer and Member of the Executive Board
Michael Wolff Jensen L.L.M. Executive Vice President, Chief Legal Officer and Member of the Executive Board
Mads Bodenhoff Senior Vice President of Finance and Principal Accounting Officer
Timothy J. Lee Senior Director of Investor Relations
Flemming Steen Jensen Executive Vice President of Product Supply and Quality
Dr. Kennett Sprogoe Ph.D. Executive Vice President and Head of Research and Product Development
Dr. Stina Singel M.D., Ph.D. Executive Vice President and Head of Clinical Development for Oncology
Joseph Kelly Head of U.S. Commercial of Endocrinology

Latest SEC Filings

Date Type Title
May 16, 2024 6-K Report of foreign issuer
May 14, 2024 6-K Report of foreign issuer
May 2, 2024 6-K Report of foreign issuer
May 2, 2024 6-K Report of foreign issuer
May 2, 2024 6-K Report of foreign issuer
Apr 24, 2024 6-K Report of foreign issuer
Apr 10, 2024 6-K Report of foreign issuer
Mar 27, 2024 6-K Report of foreign issuer
Mar 14, 2024 6-K Report of foreign issuer
Mar 7, 2024 144 Filing